Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer

GlobeNewswire February 6, 2017

GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

GlobeNewswire January 30, 2017

New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported

GlobeNewswire January 25, 2017

Advaxis Provides 2017 Business Outlook

GlobeNewswire January 9, 2017

Research Reports Initiation on Biotech Stocks -- Puma Biotechnology, Seattle Genetics, Advaxis, and BioCryst Pharma

PR Newswire January 6, 2017

Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations

GlobeNewswire December 7, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc.

Business Wire November 18, 2016

Advaxis to Present at the Jefferies 2016 London Healthcare Conference

GlobeNewswire November 15, 2016

Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

GlobeNewswire November 11, 2016

Lifshitz & Miller Law Firm Announces Investigation of Advaxis, Inc., Banc of California, Inc., Biogen Inc., Franklin Resources, Inc., Juniper Pharmaceuticals, Inc., Opus Bank, Taro Pharmaceutical Industries Ltd., and Tyson Foods, Inc.

PR Newswire October 28, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc. - ADXS

PR Newswire October 27, 2016

Biotech Stocks on Investors' Radar -- Advaxis, Cerus, Kite Pharma, and Cerulean Pharma

PR Newswire October 27, 2016

Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2

GlobeNewswire October 24, 2016

Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck

GlobeNewswire October 20, 2016

Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program

GlobeNewswire October 13, 2016

Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster

GlobeNewswire October 11, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc.

Business Wire October 10, 2016

Advaxis CSO Invited to Speak at Immune Profiling World Congress

GlobeNewswire October 6, 2016

Advaxis Appoints Christopher Duke as Chief Operating Officer

GlobeNewswire October 3, 2016

Advaxis’ Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting

GlobeNewswire September 26, 2016